Table 5.

Individual Risk Factor Model for Poor Medication Adherence*

VariableRisk FactorAt-Risk Group, n (%)P ValueOR95% CI
Patient raceBlack vs white56 (60.9)0.0391.981.04–3.77
Diabetes mellitusYes vs no41 (44.6)0.0043.261.47–7.21
ACE inhibitor monitored by EMDNo vs yes61 (66.3)0.0402.091.04–4.20
Lower patient centeredness≤2.33 vs >2.33 or missing34 (37.0)0.0392.891.05–7.93
Less patient assertiveness≤0.22 vs >0.22 or missing32 (34.8)0.0143.231.26–8.25
Less psychosocial focus≤0.48 vs >0.48 or missing67 (72.8)0.0073.311.38–7.95
Less discussion about patients’ sociodemographic circumstances≤4.7 vs >4.7 or missing61 (66.3)0.0094.041.42–11.5
Less discussion about antihypertensive medications≤1.53 vs >1.53 or missing31 (33.7)0.0373.261.08–9.89
  • ACE indicates angiotensin-converting enzyme; CI, confidence interval; EMD, electronic monitoring device; and OR odds ratio.

  • * Poor medication adherence is defined as mean adherence and adherence variability of the adaptively generated adherence types.

  • Of 92 patients.

  • P values and CIs using empirical z tests based on generalized estimating equations estimation and exchangeable intraphysician correlations.